All stock lists
Braskem SA (New York Stock Exchange:BAK)
BR · Delayed Price · Currency is USD
Basic Materials · Chemicals
1.35+0.25 (+22.73%)
Market cap
$538M
Insider Score
Health Score
Analyst consensus
Listed since
Jan 13, 1999
Website
Insider Score
––Not scored
BAK Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Distressed
From BAK’s reported statements · Q2 2026 (trailing 12 months)
Profitability6 / 20
Loses money on what it sells.
- Revenue
- $70.60B
- Net income
- -$5.54B
- Net margin
- -7.8%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $68.30B
- Cash
- $3.93B
- Net debt / EBITDA
- 6.92x
Liquidity4 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $29.30B
- Current liabilities
- $38.00B
- Current ratio
- 0.77
Cash generation4 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$5.72B
- Free cash flow
- -$8.80B
- FCF margin
- -12.5%
Dilution & runway2 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 398.3M
- Share growth (1y)
- -0.1%
- Cash runway
- 8 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
BAK Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 21.71 B | 15.49 B | 16.10 B | 17.30 B | 17.86 B | 19.46 B |
| Revenue Growth (YoY) | 21.60 % | -20.41 % | -15.93 % | -18.65 % | -6.39 % | 8.59 % |
| Cost of Revenue | 16.40 B | 14.39 B | 16.65 B | 16.86 B | 17.50 B | 18.15 B |
| Gross Profit | 5.32 B | 1.10 B | -552.00 M | 436.00 M | 362.00 M | 1.31 B |
| SG&A Expense | 1.21 B | 1.22 B | 1.17 B | 1.11 B | 1.21 B | 1.18 B |
| R&D Expense | 103.00 M | 102.00 M | 105.00 M | 121.00 M | 108.00 M | 126.00 M |
| Operating Expenses | 1.31 B | 1.32 B | -665.00 M | 1.36 B | 1.32 B | 1.21 B |
| Operating Income | 4.00 B | -217.00 M | 113.00 M | -929.00 M | -958.00 M | 99.00 M |
| Pretax Income | 3.56 B | 953.00 M | -540.00 M | -2.59 B | -530.00 M | 816.00 M |
| Tax Provision | 238.00 M | -293.00 M | 10.49 B | -2.42 B | -140.00 M | 184.00 M |
| Net Income | 3.33 B | 1.45 B | -10.29 B | -26.00 M | -267.00 M | 698.00 M |
| EPS (Basic) | 8.34 | 3.64 | -26.18 | -0.07 | -0.66 | 1.76 |
| EPS (Diluted) | 8.34 | 3.64 | -26.18 | -0.07 | -0.66 | 1.76 |
| Shares Outstanding | 398.28 M | 398.60 M | 398.60 M | 398.48 M | 398.48 M | 398.48 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.